{"entity":{"id":"nct07008716","kind":"trial","name":"Omitting CTV for Primary Tumor in LS-SCLC","aka":[],"tldr":"A phase 3 trial of etoposide, carboplatin and cisplatin in lung cancer, run by Sun Yat-sen University, now recruiting.","summary":"Omitting CTV for Primary Tumor in LS-SCLC is a phase 3, randomised interventional study registered as NCT07008716 by Sun Yat-sen University, with a registry enrolment figure of 852 participants, started 2025-06-03 and due to reach its primary completion in 2027-12-31. Interventions recorded: Radiation Therapy; Etoposide + carboplatin; Etoposide + cisplatin; Creating CTV for primary tumor; prophylactic cranial irradiation (PCI). Conditions listed: SCLC, Limited Stage; Radiation Exposure; Radiotherapy Side Effect; Progression. Primary outcome: Local progression free survival; Severe toxicity free survival. Lung eligibility wording from the registry: \"Small cell lung cancer confirmed by histology or cytology; TNM stage IA-IIIC (AJCC 8th edition, 2017; limited-stage) without intrapulmonary metastasis;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07008716","url":"https://clinicaltrials.gov/study/NCT07008716"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["limited-stage-sclc"],"sections":[],"technologies":["cytotoxic-chemotherapy","imrt-igrt","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["etoposide","carboplatin","cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07008716","phase":"3","setting":"Omission of Clinical Target Volume (CTV) for Primary Tumors in Limited-Stage Small Cell Lung Cancer: A Prospective Multicenter Randomized Controlled Trial","sponsor":"Sun Yat-sen University","enrolled":852,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07008716/","neighbours":{"cancer":[{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}